2m 2m 2m 2m 2m 2m 2m
- $9.2BMarket Cap
- -61.39%1-Year Change
- Medical DevicesIndustry
Insulet (PODD)
Key Performance
More- Earnings Score: 99
- Momentum Score: 9
- True Yield: N/A
- Financial Health Score: 100
Latest Research & News
Rosen Law Firm has filed securities class action lawsuits against Blaize Holdings, Inc. and Hyliion Holdings Corp., alleging false statements and improper revenue recognition. Investors who purchased securities during specified periods are encouraged to join the class action before the October 5, 2026 deadline for lead plaintiff status. The firm is also handling a case against Insulet Corporation with an August 31 deadline.
08/29/2026, 7:51 PM • GlobeNewswire
Rosen Law Firm has filed class action lawsuits against Hyliion Holdings Corp. (HYLN) for alleged false statements regarding a business deal with a recently formed entity lacking actual operations, and potential insider trading by executives. A separate class action has been filed against Insulet Corporation (PODD) with an August 31, 2026 deadline for lead plaintiff motions. Both lawsuits allege material misstatements that caused investor losses.
08/29/2026, 6:36 PM • GlobeNewswire
Rosen Law Firm reminds investors in Insulet Corporation (PODD) and Primoris Services Corporation (PRIM) of important class action lawsuit deadlines. Investors who purchased securities during specified periods and suffered losses exceeding $100,000 are encouraged to secure legal counsel before the August 31, 2026 deadline to potentially recover damages through contingency fee arrangements.
08/29/2026, 5:55 PM • GlobeNewswire
Rosen Law Firm reminds investors of Insulet Corporation who purchased securities between February 21, 2025 and May 26, 2026 of the August 31, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Insulet made false statements regarding defective manufacturing controls and procedures that created safety risks, resulting in investor damages.
08/29/2026, 5:55 PM • GlobeNewswire
Rosen Law Firm is notifying investors in Primoris Services Corporation (PRIM) and Insulet Corporation (PODD) about ongoing securities class action lawsuits. Primoris investors who purchased stock between August 5, 2025 and June 22, 2026 can join the class action with a September 21, 2026 deadline for lead plaintiff status. The lawsuit alleges Primoris made false statements about cost estimation and project management for renewable energy projects, leading to material cost overruns. Insulet investors face an August 31, 2026 deadline.
08/29/2026, 5:36 PM • GlobeNewswire
Rosen Law Firm is encouraging investors who suffered losses exceeding $100,000 in Primoris Services Corporation (PRIM) and Insulet Corporation (PODD) to join securities class action lawsuits. The PRIM lawsuit alleges the company made false statements regarding cost estimation and project management for renewable energy projects, leading to significant cost overruns. The PODD lawsuit details are partially provided. Both cases have approaching deadlines for lead plaintiff applications.
08/29/2026, 5:36 PM • GlobeNewswire
A class action lawsuit has been filed against Insulet Corporation alleging that the company made materially false and misleading statements regarding its business operations and compliance policies. The complaint specifically claims that Insulet's manufacturing controls were defective, creating a foreseeable risk that products could violate safety regulations. Investors who purchased Insulet securities between May 21, 2025 and May 26, 2026 are encouraged to join the lawsuit, with a lead plaintiff deadline of August 31, 2026.
08/27/2026, 12:00 PM • GlobeNewswire
Rosen Law Firm is alerting Insulet Corporation investors who purchased securities between February 21, 2025 and May 26, 2026 about an August 31, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Insulet made false statements regarding defective manufacturing controls and procedures that created safety risks, resulting in investor damages.
08/26/2026, 5:22 PM • GlobeNewswire
Pomerantz LLP filed a class action lawsuit against Insulet Corporation (PODD) for alleged securities fraud. The complaint alleges that Insulet made false statements about its manufacturing controls and failed to disclose defective procedures that created safety risks. Two voluntary medical device corrections were announced in March and May 2026, resulting in significant stock price declines of 6.88% and 5.07% respectively. Investors who purchased Insulet securities between February 21, 2025 and May 26, 2026 can join the class action.
08/25/2026, 4:58 PM • GlobeNewswire
Insulet CEO Ashley McEvoy purchased 1,100 shares worth approximately $162,217 at a weighted average price of $147.47 per share on August 21, 2026, increasing her total beneficial ownership to 23,735 shares valued at $3.52 million. The insider buy comes after the stock declined 55% over the preceding year and is viewed as a bullish signal, suggesting McEvoy's confidence in the company's ability to reverse its bearish trend under her leadership since April 2025.
08/24/2026, 9:13 AM • The Motley Fool
PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP has filed a class action lawsuit against Insulet Corporation for securities violations, alleging the company made false and misleading statements regarding defective manufacturing controls and safety risks. The lawsuit covers the period from February 21, 2025 to May 26, 2026, with a deadline of August 31, 2026 for investors to participate.
08/07/2026, 9:45 AM • GlobeNewswire
Grabar Law Office has filed federal securities fraud class action investigations against four companies: Erasca for misleading statements about its ERAS-0015 drug candidate and undisclosed patent risks; Insulet for defective manufacturing controls leading to voluntary product corrections; Power Solutions for overstating sales demand and understating manufacturing costs; and PROCEPT BioRobotics for using undisclosed discount programs that artificially inflated sales and created excess inventory. Shareholders who purchased shares during specified periods are eligible to seek damages and corporate reforms.
08/07/2026, 9:32 AM • GlobeNewswire
Law Offices of Howard G. Smith announced class action lawsuits against three publicly-traded companies for securities fraud. Insulet Corporation faces allegations of defective manufacturing controls, Microvast Holdings is accused of overstating margin targets and expansion timelines, and Hub Group is charged with material misstatements in financial reporting. Investors have until late August and September 2026 to file lead plaintiff motions.
08/04/2026, 2:15 PM • GlobeNewswire
Insulet Corporation (PODD) faces a class action securities fraud lawsuit alleging the company failed to disclose defective manufacturing controls that led to two voluntary medical device corrections in March and May 2026. The disclosures caused significant stock price declines of 6.9% and 5.1% respectively. Investors who purchased shares between February 21, 2025 and May 26, 2026 have until August 31, 2026 to file a lead plaintiff motion.
08/04/2026, 1:40 PM • GlobeNewswire
Grabar Law Office has launched investigations into potential securities fraud and fiduciary duty breaches at four major companies: Erasca (ERAS) for misleading statements about its ERAS-0015 drug candidate and undisclosed patent risks; Insulet (PODD) for defective manufacturing controls leading to voluntary product corrections; Power Solutions International (PSIX) for overstating sales demand and understating manufacturing costs; and PROCEPT BioRobotics (PRCT) for using undisclosed discount programs that artificially inflated sales figures and created excess inventory.
08/04/2026, 11:49 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 09/11/2026
Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Key Executives
- Ashley A. McEvoy
- Eric Benjamin
- Flavia H. Pease
- John Wodick Kapples
- Prem Singh
Current Ownership Distribution
- Mutual Funds1.7B (55.40%)
- Institutions1.3B (44.24%)
- Insiders10.8M (0.36%)
- Other0 (0.00%)